Certolizumab pegol (Cimzia®) [in combination with methotrexate]
All Wales Medicines Strategy Group (AWMSG)
Record ID 32014001452
English
Authors' recommendations:
Certolizumab pegol (Cimzia®), in combination with methotrexate, is recommended as an option for use within NHS Wales for the treatment of active psoriatic arthritis in adults when the response to previous disease modifying antirheumatic drug therapy has been inadequate. Certolizumab pegol can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/1713
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Methotrexate
- Arthritis, Psoriatic
- Immunoglobulin Fab Fragments
- Polyethylene Glycols
- Antibodies, Monoclonal, Humanized
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.